- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.08. | TRANSTHERA-B (02617): DATE OF BOARD MEETING | - | HKEx | ||
| TRANSTHERA SCIENCES Aktie jetzt für 0€ handeln | |||||
| 07.08. | TransThera's resistant biliary cancer drug cleared in China | - | pharmaphorum | ||
| 07.08. | TRANSTHERA-B Opens ~15% Higher as Proprietary New Drug 'Yochanra' Approved for Market Launch | 1 | AASTOCKS | ||
| 06.08. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT MARKETING APPROVAL FOR YOCHANRA (TINENGOTINIB TABLETS) GRANTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | - | HKEx | ||
| 24.07. | TRANSTHERA-B (02617): GRANT OF SHARE AWARDS AND SHARE OPTIONS UNDER THE H SHARE AWARD SCHEME | 1 | HKEx | ||
| 17.07. | TRANSTHERA-B (02617): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 10.07. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT APPROVAL FOR CONDUCTING CHINA PHASE II CLINICAL TRIAL OF TT-00973 TABLETS IN COMBINATION WITH FIRMONERTINIB ... | 2 | HKEx | ||
| 06.07. | TransThera Completes Late-Stage Trial Enrollment For Bile Duct Cancer Drug | 3 | Benzinga.com | ||
| 01.07. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT ENROLLMENT COMPLETED IN THE GLOBAL MULTICENTER REGISTRATIONAL PHASE III CLINICAL TRIAL OF TINENGOTINIB MONOTHERAPY ... | 2 | HKEx | ||
| 01.07. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT APPROVAL GRANTED FOR PHASE II CLINICAL TRIAL IN CHINA OF TT-01488 TABLETS IN COMBINATION WITH ANTI-CD20 MONOCLONAL ... | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE STRATEGY COMMITTEE OF THE BOARD OF DIRECTORS | 2 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE REMUNERATION AND APPRAISAL COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 18 JUNE 2026; (2) CHANGE OF THE INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMPOSITION ... | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 18 JUNE 2026; (2) ADOPTION OF THE H SHARE AWARD SCHEME; AND (3) AUTHORIZATION ... | 1 | HKEx | ||
| 12.06. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF OPERATING OFFICER | 1 | HKEx | ||
| 27.05. | TRANSTHERA-B (02617): NEXT DAY DISCLOSURE RETURN | - | HKEx |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMYLYX PHARMACEUTICALS | 38,660 | 0,00 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| MODERNA | 123,92 | -0,26 % | BREAKING: AKTIONÄR-Depotwert Moderna explodiert! | Ein Durchbruch der mRNA-Technologie im Bereich der Onkologie: Moderna und der Entwicklungspartner Merck & Co haben die lang ersehnten ersten Ergebnisse der Phase-3-Studie INTerpath-001 mit Intismeran... ► Artikel lesen | |
| BIONTECH | 99,80 | -0,05 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| QIAGEN | 37,565 | -3,02 % | DAX Gewinner am Mittwoch: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| BEAM THERAPEUTICS | 29,760 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 375,86 | 0,00 % | Raymond James raises Praxis Precision Medicines price target on pipeline outlook | ||
| APOGEE THERAPEUTICS | 134,73 | -0,01 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| SUMMIT THERAPEUTICS | 13,150 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| COGENT BIOSCIENCES | 36,710 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,495 | -0,14 % | Recursion, Novavax and Crispr Stocks Trending in Pre-Market-Here's Why | ||
| ENLIVEN THERAPEUTICS | 59,94 | +0,19 % | William Blair startet Coverage für Enliven Therapeutics mit "Outperform" | ||
| MONTE ROSA THERAPEUTICS | 14,300 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 119,91 | +0,09 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 38,150 | 0,00 % | Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile | WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,440 | 0,00 % | H.C. Wainwright raises Relay Therapeutics price target to $29 |
TRANSTHERA SCIENCES NANJING INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,010 (-0,94 %) liegt der Kurs bei 1,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSTHERA SCIENCES NANJING INC finden Sie auf Wallstreet Online.